As noted above, we have determined that a i p l e transmission-emission planar method can be used to provide absolute quantitation of raaionuclides in large volume sources such as the liver. Since the volume can be determined with SPECT or X-ray CT, the concentration of activity in this organ can be provided for dosimetry. For smaller organs such as the spleen, kidneys, tumor sites, etc., the transmission-emission method underestimates radionuclide content because of scattered photons from background activrty and other large sources in the body. A contrast recovery method needs to be evaluated as a possible way of reducing the overestimated background around small organs.
Most quantitative SPECT methods developed for Tc-99m have not been tested for 1-131. Because of the high energy and significant septal penetration with 1-131, correction factors must be determined that are unique for this radionuclide. A solution to subtraction of the scatter fraction events for 1-131 will also be more complicated because photons greater than the upper limit of the 1-131 collimator are emitted by 1-131. Scatter subtraction, deconvolution and Monte Carlo methods need to be tested for 1-131 SPECT.
Finally, the intent is to develop or modify existing methodology to integrate information from various tomographic imaging modalities, eg, X-ray/CT scan, and MRI. Summation of Area Methods Transmission computerized tomography (TCT) offers an accurate means to estimate volumes in vivo. Most attempts at volume determination using TCT have dealt with the summation of area methods. This is one of the simpler and more practical means of calculating organ or tumor volumes using contiguous TCT slices. The accuracy of these volume determinations using the summation of area technique is in the range of t 5%. Taking a single TCT slice, the cross sectional area of any organ of interest is automatically computed by software programs built into modern TCT units. A TCT cursor outlining the organ will give an accurate area. The volume of a specific organ then may be determined by addition of areas obtained on sequential TCT scans. Volume is thus the Summation of areas times the scan widths. While most anatomical structures conform to a prolate spheroid, error in this method is caused by abrupt changes in contour of an object.
This method can also be used for determining specific tumor volume because of the predictabilrty of tumor shape. A small tumor may be encompassed by a single cross-section.
If a large tumor is evaluated, the TCT cursor is used to outline the anatomical section and contiguous TCT cuts are obtained; volume is once again determined by summation of the contiguous areas times TCT scan spacing. Accuracy for smaller tumors is affected by section sampling problems.
b. Emission Computerized Tomography (ECT)
Rollo has described a manual method and Eikman, a computer-assisted method for estimating liver volume (mass) from planar images obtained after administration of radiopharmaceutical. DeNardo and Larson have described similar methods for the estimation of splenic weight. The accuracy of any of these methods when compared to organ weight at autopsy h a s been better than f 5%. These methods require certain assumptions for organ shape. Kan and Yamamoto have used SPECT to determine liver volume. The advantage of SPECT is its independence of configuration, since no geometric assumption is necessary. All of these methods are dependent upon accumulation of radioactivity in normal tissue to define its boundaries or those of the tumor.
Using SPECT we propose to develop methods and software to determine tumor volume after the accumulation of radioactivity (labeled antibody) in the tumor itself. The mechanics and methods of calculation are straight forward and similar to those for TCT, and in routine use for determination of ventricular volumes of the heart. Edge definition can be obtained either manually or using computer programs. Non-uniformity of distribution of labeled antibody within the tumor at the microscopic level represents no problem to these gross determinations of volume. Gross non-uniformity as may occur with substantial tumor necrosis represent a potential problem affecting estimates of tumor mass (and radiation dosimetry). Since the necrosis is likely to be central, it probably will not affect edge definition. Furthermore, the volume of necrosis can also be estimated , when gross, by the same methods used for the entire tumor. Combination of TCT and ECT tumor volume estimates can be expected to provide accuracy adequate for the purposes of this project. Accurate volume measurements also provide an important objective basis for judging therapeutic efficacy.
Absolute quantitation of radioactivity in vivo is a formidable task, atthough the methodology has advanced remarkably in recent years. Budinger, Kuhl and Hoffman have reviewed the considerations and problems. Holman has concluded that single photon SPECT is capable of: measurement of organ or tissue volume, measurement of rate of appearance or disappearance of radiotracer, and ~ measurement of the tracer biodistribution. Jaszczak, while appreciating the limitations of available photon flux and the resutting root mean square noise level, concluded that absolute volumes and regional radionuclide concentrations using single photon SPECT if the system characteristics are determined . Kuhl has successfully used these methods to assess regional blood flow in a more complicated structure, the brain. Calculation of the radiation absorbed doses in RIT depends on accurate in vivo quantitation of radionuclide uptake in tumors and other organs that accumulate different concentrations of the radiopharmaceutical administered to a patient. Since only a small fraction of the total COUntS recorded from 1-131 with a 1/4 or 3/8 inch thick Nai crystal are photopeak events the total count rate response of a camera for radionuclides such as Tc-99m have little value in predicting t h e response of the camera for 1-131. Preliminary studies with a range of 1-131 sources imaged in air with a Siemens 7500 gamma camera indicated that at photopeak count rates of 25,000 cps, more than half the events were lost due to the resoking time d the gamma camera.
a.
Dead Time Correction of Planar Gamma Camera Images:
For a gamma camera spectrum the true count rate for the photopeak is given by:
where T = Resolving Time/window fraction For 1-131 and the 1/4' thick Nal detector of a typical gamma camera, the window fraction is typically only 12% of the entire spectrum when imaging a liver in a patient, so that the apparent dead time can be significantly increased compared with the true dead time.
The exact value of the window fractim depends on 'the source depth, shape, distribution of sources in the body, etc.
A correction for dead time could be made by either acquiring all frames in live time, or using a standard source that is imaged in every frame. Live time mode acquisition can only be implemented if the total gamma ray spectrum is accessible and passed through the amplifier and single channel analyses of the camera Another approach is to add a standard source to every camera image and compare the counts from each frame with an image of the standard alone in air. The ratio of these counts can be used to provide a correction for each frame. The true counts are obtahd as follows:
where N(sa) are the counts from the standard in air and N(sf) are the counts detected from ?he standard added to the frame.
The advantage of this approach is that it measures the actual response of the detector for the photopeak events which may only be a small fraction of the total spectrum. The method is simple to use and adds no increase in time to acquisition of an image.
However, the method can only be used for correction of resolving time errors if the photopeak shape and position are preserved. At high count rates, movement and distortion of the photopeak and changes in shape of the spectrum, together with smearing of events in the camera image make retrospective correction with a standard less accurate.
b. Correction of whole body scan images for dead time:
In the case of whole body scan image, correction for the resolving time cannot be made using the usual resolving time method because the count rate of the camera is changing with position over each source in the body. Since each area of the image is viewed for the 'exposure' time by the moving camera. A simple solution to this problem is to place a source of known activity in the field of view of the camera over the entire scan period. A line source of constant linear activity could be imaged along the length sf the whole body couch to provide this correction factor for evefy line of pixels alang the width of the field of view. A simpler solution is lo attach a source to the collimator that is outside the field of view of the whole body. The number of counts detected from this standard source can then be used to correct each line of pixels in the whole body image.
A computer program coufd be designed that would automatically make this correction to each line o f pixels, based on a correction factor derived from:
where N(so) are the counts detected from the standard with no other source N(st) are the counts from any line of pixels across the width of the patient.
A whole body scan image should be acquired with the standard attached to the collimator and no source on the whole body couch to find N(so) for every line of pixels in the whole body image.
For conjugate view images, the counts from the source should be attached in some way to the collimator to permit correction for attenuation in the whole body couch.
Dead Time Correction for SPECT Imaging:
The projection images acquired with a rotating gamma camera can be influenced by the resolving time of the gamma camera. The reconstructed image will be modified by the changing fraction of counts lost in individual projection images.
If a correction factor can be applied for each projection image, the --ansverse section images reconstructed from modified projection data would be . *rinsically correct.
Since the depth of a source will modify the gamma ray spectrum recorded by the gamma camera, correction of SPECT data will depend on adding an image of a standard to every projection frame and retrospectively correcting the projection image data before reconstruction.
The number of counts in a individual pixel in the corrected projection image is given by:
where P'(r,O) is the count in the projection image at (position (r,O) and alone to the counts in each image.
P(r,O) is the acquired count at (r,O) CF(r,O) is the correction factor at (r,O) given by the ratio of counts in air
Errors introduced in SPECT by neglecting the resolving time of the camera can be significant and the distortion introduced by varying count losses in each projection image may result in unpredictable artifacts in the section images. Correction for the dead time of the gamma camera in SPECT is an important problem that needs to be addressed if quantitation SPECT can be used for dosimeter estimates.
Determination of Specific Uptake of MoAb in Tumors and Organs:
When the fraction of an administered r a d i o p h a r~~c~~~~a~ in a tumor site or organ visualized in a gamma camera image is determined from the number of counts detected in a gamma camera image, background subtraction methods are used in an attempt to subtract the activity in tissue overlying and underlying an area of interest in the pianar gamma camera image. The number of counts detected in the organ is then converted to activiry and expressed as a fraction of the administered dose. The temporal pattern of counts detected is a reflection of the activity in an organ or tumor site plus a fraction that reflects the intra-organ blood volume. A method is required that can be used to determine the specific uptake or accumulation of the MoAb in the organ or tumor site since this reflects the metabolic state of the site of uptake.
The specific uptake for a radiopharmaceutical that remains in the vascular pool for a significant
time compared with the rate of specific uptake can be determined using a dual tracer method. A simpler method that depends on detecting the temporal change in activity detected in the blood pool and a selected organ or tumor site can be used if the specific uptake pattern is slow and serial blood samples can be drawn to determine the percent injected dose retention in whole blood or plasma. The method proposed relies on calibrating the gamma camera image acquired at any time post injection with the activii measured in whole blood.
Suppose the number of counts detected from the tumor at time t post injection is N (t) given by: If the counts in a region of interest drawn immediately post injection are determined as N/O), and the cocints in a l m l blood sample are measured at the same time, a calibration factor for any subsequent image can be derived from:
where N(bl) are the counts per min from the whole blood sample as determined with a Nal well counter.
At any time post injection the fraction of counts in the tumor ROI can be obtained by interpolation of the blood retention data. The number of counts to be subtracted from any organ or tumor site can thus be easily subtracted to yield an estimate of the specific uptake at any time post injection.
4.0
Derivation of S Factors for RIT Dosimetry:
The MIRD S factor tables have been calculated for standard man assuming that each organ has defined volume and shape. Use of these S factors in RIT dosimetry can lead to significant errors because individual organs in patients can differ by a significant factor due to body size and disease. The spleen for example can vary by a fador of more than three compared with the volume used in standard man. Tumor volumes of difference shape and volume require S factors to calculate the estimated radiation absorbed dose.
Three methods of deriving S factors for tumors and organs in the body need to be developed and compared. The three dimensional activity and volume information provided by quantitative SPECT will be used as input for the methods planned as part of the UCDMC research program.
a.
b.
Investigate whether simple interpolation of the S factors or absorbed fractions listed in the MlRD tables can be used to derive S factors for uptake volumes that differ from the values used for standard man.
Derived S factors from convolution of a spatially invariant point source dose distribution over the three dimensional distribution of activlty provided by SPECT. A fast Fourier 
OBJECTIVES AND APPROACH
Antibodies themselves are considered to be noncytotoxic and eliminate tumor cells by activating some host-effector mechanism(s). Previous studies suggest that the ability of these effector mechanisms to eliminate cells is limited and it appears unlikely that unmodified antibodies alone will be very useful in treating bulk disease. Howeve,, there is evidence that huri,oral and cellular response to some antibodies is associated with effective antitumor activrty in nude mice with human xenographs and in a few human patients. Of particular importance to this program in the evidence that this biologic response may provide us with a Yherapeutic window' of increased tumor blood flow and vascular permeability to enhance delivery of aumorcidal immunoconjugates.
Over the past ten years we have worked with several monoclonal antibodies, both in the development of new immunoradiopharmaceuicals for therapy as well as in the development of quantitative imaging of these pharmaceuticals in patients. Our initial work was with Lym-1 in lymphoma followed by L-6 and its human chimera (Ch-L6). We have observed evidence for invivo biologic activity and enhanced tumor uptake. Phase I therapy studies in lymphoma and breast cancer have demonstrated measurable tumor regression. However for breast cancer and other adenocarcinomas the therapeutic index, (particularly the tumor radiation to normal marrow radiation ratio) must be further increased to achieve an effective therapeutic approach in these non-radiosensative neoplasms. The development of radiopharmaceuticals with thesc 2nd other unique MoAb's carefully chelated with radiometals such as Cu-67 or Y-90 with shorter physical hatf lives, but longer effective T 1/2 in tumor tissue than radioiodines should enhance the therapeutic index and thus the therapeutic potential of this approach.
L-6 MoAb and its human chimera (Ch L-6) have provided us with the initial approach to adenocarcinomas using biologically active radioimmunoconjugate therapy for metastatic breast cancer. These antibodies are well described and have excellent cytotoxic, immunologic, and histopathologic characteristics. L-6 identifies, abundant, non-shed antigen that is strongly expressed in most human carcinomas including carcinomas of the lung, breast, colon, and ovary. to our arsenal. The human chimera of this MoAb has been developed ?nd will be available to use in a biologically active form.
Single-chain antigen-binding proteins produced by recombinant techniques have been suggested to have high potential in cancer therapy. In ouf opinion they provide the crutial building blocks to initiate designer molecules for antibody based radiopharmaceuticals containing the messages for tumor targeting and vascular permeabilq as well as radiometal chelates and effective linkage. Our previous sequencing and PCR of the Lym-1 antibody allow us to utilize these methods to create a single-chain version of this antibody. The protein produced can then be modified to improve the properties of our immunoconjugates. We have isolated and expanded the DNA. The synthetic gene encoding the single chain antibody form of Lym-1 will now be created using standard techniques to ligate restridon fragments of specific DNA. The nucleic acid linkers (EcoR1 and Barn H1) will be purchased. The OL/PR hybrid promoter site will be created by isolation of the two fragments from lambda DNA via restriction digest and subsequent ligation at the Hinc 2 site as showm in Figure (following section 3) . Two portions of the sequencr will be synthesized by machine, the segment stretching from the Dde 1 site to the Tthl11 I Siie (encoding the ompA signa! peptide with flanks), and the segment from the Ava 1 site to the Ava 2 site (encoding the peptide linker with flanks). The DNA coding for the Lym-1 light chain variable region will be obtained by Tth111 4lAva 1 digest of PCR material already prepared from our varified PCR material, using a primer to incorporate the two stop codons on !hs end of the variable region message. The final product shown will then be digested with Bam H1 and EcoRl and inserted into a pUC plasmid for selection, growth and expression in E. coli.
A very small group of antibodies have been found that are relatively tumor specific and are internalized into the tumor cell once they attach to the abnormal membrane molecule. There is some evidence that these target molecules may be abnormal receptors but little more is presently well known about the mechanisms of internalization. The BR-96 anti-adenocarcinoma antibody is a relatively tumor specific antibody which is quickly internalized after attaching to the cell surface of adenocarcinoma cells in vitro. Electron micrographs demonstrate intracytoplasmic distribution but further details are not known at this time. We have performed murine biodistribution studies with this antibody using In-1 11 BR-96 and a human breast cancer cell line in nude mice and have demonstrated excellant tumor uptake and relative low normal tissue uptake (Figure 2 ). FIGURE 2 r:
Tumor therapy in vitro and in the human breast cancer xenograph in nude mice has been initiated to study the relative therapeutic efficacy of 1-131, An escalating dose therapy protocol will be performed with Cu-67 Lym-1 with this DOTA linkage.
However, although the radiation dosimetry is quite favorable, the high liver uptake and slow release of Cu-67 is not optimal. We pian to study the newer linkages of and changes in the macrocycle in order to diminish this hepatic uptake and long residence time.
Cu-67 and In-1 1 1 /Y-90 labeled Ch L-6 and Br-96 pharmacokinetics will be compared in animals and patients. If appropriate kinetics are demonstrated on these studies then the feasibility of therapy in patients will be tested.
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SIGNIFICANCE
Tumor response rates greater than 70% have been achieved in forty patients with B-cell malignancies and four patients with breast adenocarcinoma resistant to conventional therapies, when 7371 Lym-1 or 7371 L-6 MoAb were used. These results were achieved in patients with advanced disease and no other options, and despite the fact that we are only now approaching the MTD for the systems. Complete remissions have uniformly occurred at the highest dose level of 7 3 f l per d in a small number of lymphoma patients. A variety of enhancement strategies are proposed lor future exploration.
As has been stated, lymphoma patients who fail their initial therapy, have only available the prospects of decreasing responsiveness and increasing toxicity to chemotherapy. In adenocarcinoma the picture is also generally bleak. Particularly in breast cancer where one of every ten women in the United States will develop breast cancer, and of these one third will die of their disease. It is estimated that there will be 150,000 new breast cancer diagnoses, and 44,OOO breast cancer deaths in 1990. Despite improved diagnostic technology and increased public awareness enabling earlier detection of the disease; despite the development of new chemotherapy agents, more aggressive regimens with use of autologous bone marrow rescue technology and higher quality radiation therapy; and despite continuous combination and recombination of available modalities of therapy there has been no change over the last 50 years in survival rate for patients who develop metastatic breast cancer. Recent attempts at treating cancer patients with monoclonal antibodies has met with variable success. In the field of breast cancer, no benefit has heretofore been demonstrated. We thus present a new approach to the treatment of metastatic breast cancer using quantitative imaging and extrapolated dosimetry to determine the likely toxicity risks and therapeutic benefits of serial radioimrnunotherapy. Using this approach, regression of far advanced tumor has occured in 4 of the first 5 patients treated. This has been accomplished with acceptable side effects.
The significance of this type of advancement in the face of these odds is remarkable. However, to be effective as clinical therapy in most metastatic cancer patients the therapeutic index of radioimmunotherapy be further enhanced. 1-1 31 radioactivity circulating in the marrow for several days in the marrow blood pool is the major contributor to marrow toxicrty. The strategies planned in this program are expected to significantly enhance the therapeutic index of tumor to marrow and thus make these early Yherapeutic successes' move into practical clinically significant therapeutic approaches for cancer therapy.
